SRSusana Rives

Susana Rives

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susana Rives has a total of 531 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL

    by Stephan A. Grupp, Shannon L. Maude, Susana Rives, Hidefumi Hiramatsu, Andre Baruchel, Peter Bader, Henrique Bittencourt, Jochen Buechner, Theodore W. Laetsch, Barbara De Moerloose, et al.

    We report the 5-year analysis of tisagenlecleucel in 79 pediatric and young adult patients with relapsed or refractory (r/r) B-cell ALL (B-ALL) from the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849 ), with a median follow-up of 79.4 months. Tisagenlecleucel was administered as a single infusion with dosing normalized by weight in patients ≤50 kg. Key long-term end points included relapse-free survival (RFS), overall survival (OS), and safety. Censoring included loss to follow-up, withdrawal of consent, new anticancer therapy (± stem cell transplantation [SCT]), and death. The estimated 5-year RFS among responders (n = 70) with and without inclusion of SCT in censoring for new anticancer therapies was 47.3% and 51.0%, respectively. The median time to B-cell recovery was not reached with censoring for all further anticancer therapies, including SCT. The median OS was not reached. The estimated OS at 5 years was 55.0% and 62.4% with and without inclusion of SCT in censoring for new anticancer therapies, respectively. In total, 17 responders received a postinfusion SCT, 14 while still in complete remission. No new or unexpected adverse events were reported. These findings continue to support the potential of tisagenlecleucel as definitive therapy for many heavily pretreated pediatric and young adult patients with r/r B-ALL.


  • Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC

    by Víctor Galán-Gómez, Odelaisy León-Triana, Anna Alonso-Saladrigues, Nazaret Sanchez-Sierra, Águeda Molinos-Quintana, Blanca Herrero, Mi Kwon, Pere Barba, Anna Torrent, Mónica Cabrero, et al.

    CAR-T therapy is a powerful treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of bridging therapy prior to CAR-T infusion on patient outcomes remains insufficiently explored. In this retrospective study of patients with relapse/refractory B-ALL (N = 103), we compared outcomes across different bridging therapy groups: Low-Intensity Chemotherapy (LIC, N = 50), Immunotherapy (N = 20), or High-Intensity Chemotherapy (HIC, N = 33). At day +28 post-infusion, LIC and Immunotherapy showed significantly higher rates of Complete Remission with negative Minimal Residual Disease compared with HIC (96% vs 85% vs 75%), along with lower rates of disease progression (4% vs 10% vs 15.2%) and treatment-related mortality (0% vs 5% vs 9.1%). Additionally, patients who received three or more prior lines of therapy before CAR-T infusion exhibited significantly lower response rates. Despite potential biases, such as intrinsic disease aggressiveness or unidentified genomic alterations, present findings suggest that using LIC or immunotherapy as bridging strategies, in patients with fewer prior treatment lines, may be associated with a lower overall disease and treatment burden and could potentially contribute to improved CAR-T cell efficacy and clinical outcomes. Nevertheless, additional investigations are required to elucidate biological and clinical mechanisms by which bridging approaches and treatment history modulate CAR-T responses.

  • Open Access

    Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy

    by Valentín Ortiz-Maldonado, Jacques-Emmanuel Galimard, Giorgio Ottaviano, Anna Alonso-Saladrigues, Shatha Farhan, Sowjanya Vuyyala, Eva Michel, Fizza Imran, Nazaret Sánchez-Sierra, Nuria Martínez-Cibrian, et al.

    CD19-directed CAR T-cell therapy (CART19) has transformed relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) management, but the prognostic impact of immunotherapy sensitivity and post-allogeneic hematopoietic cell transplantation (alloHCT) relapse timing in real-world practice remains unclear. We retrospectively analyzed EBMT registry patients with R/R B-ALL treated with CART19 (2016-2023), stratifying by prior alloHCT and classifying prior blinatumomab and inotuzumab ozogamicin (InO) as naïve, responder (CR/CRi), or refractory. Among 345 patients (173/172 adults/children), median age was 18 years (range 1.1-78.2); 58% were alloHCT-exposed, 27% blinatumomab-exposed, 29% InO-exposed, and 52% had pre-lymphodepletion morphological disease. With a median follow-up of 2.3 years, the 3-month MRD-negative complete remission cumulative incidence was 78%; 2-year overall survival (OS) and event-free survival (EFS) were 65% and 49%. In alloHCT-naïve patients, 2-year OS/EFS were 83%/60% (blinatumomab responders), 65%/55% (blinatumomab-naïve), and 31%/17% (blinatumomab-refractory); for InO, OS/EFS were 68%/54% (naïve), 62%/55% (responders), and 22%/18% (refractory). In alloHCT-exposed patients, blinatumomab category did not discriminate outcomes, whereas InO refractoriness was associated with inferior OS/EFS (49%/29%) versus InO-naïve (71%/54%) and responders (60%/38%). Early relapse after alloHCT (<6 vs ≥6 months) was associated with worse 2-year OS (43% vs 74%) and EFS (31% vs 54%). In multivariable models, immunotherapy refractoriness independently predicted inferior EFS (HR 2.56 in alloHCT-naïve; HR 2.20 in alloHCT-exposed); overt morphological disease at lymphodepletion in alloHCT-naïve (HR 3.34) and early post-alloHCT relapse (HR 1.85) further worsened EFS. These findings support pragmatic pre-CAR T risk stratification and prioritization of trials or intensified strategies for refractory disease and early post-alloHCT relapse.

  • BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series

    by Georgina Morón-Cazalilla, Marina Pons-Espinal, Anna Alonso-Saladrigues, Laura Arqués, Nazaret Sánchez-Sierra, Sílvia Simó-Nebot, Julià Gotzens, Ana Valls-Lafon, Cristina Esteva, Jose L. Dapena, et al.

    Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.

  • Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy

    by Sergi Camarillas, Anna Alonso-Saladrigues, Víctor Navarro, Júlia Marsal, Águeda Molinos, Javier Delgado, Blanca Herrero, Alex Rampotas, Claire Roddie, Veit Bücklein, et al.

  • Open Access

    Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome

    by Laura M. Moser, Martin Hutter, Martina Ahlmann, Anna Alonso-Saladrigues, Andishe Attarbaschi, Francis A. Ayuk, Claudia D. Baldus, Adriana Balduzzi, Halvard Bonig, Jean-Pierre Bourquin, et al.

    This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure. CAR-T for relapse after transplant from a matched sibling donor (MSD) compared to alternative donors was associated with lower 2-year-OS (MSD 59.1%, mismatched donor MMD 80.2%, matched family/unrelated donor MFD/MUD 68.3%, p = 0.046). Two-year incidence of CAR-T failure was highest for MSD (MSD 73.8%, MFD/MUD 49.7%, MMD 52.2%, p = 0.006). Patients who had relapsed early (< 6 months post HSCT) showed inferior 2-year-EFS (23.7%) and OS (47.2%) compared to patients with late relapse, ≥ 6 months after HSCT (EFS 49.8%, p  = 0.001; OS 73.9%, p  < 0.001). Early relapse was associated with a higher incidence of CAR-T failure and relapse after tisa-cel, particularly CD19+ relapses. Outcomes correlated with disease burden at lymphodepletion: 2-year-OS was 81.7% for MRD–, 69.2% for MRD+, and 55.2% for patients in non-remission ( p  = 0.003), with incidence of CAR-T failure highest in non-remission. Prior transplant from an MSD, early post-HSCT relapse, and disease burden at lymphodepletion identify patients at increased risk of CAR-T failure after HSCT.

  • Open Access

    Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy

    by Anna Alonso-Saladrigues, Elena Esperanza-Cebollada, Clara Vicente-Garcés, Sara Perez-Jaume, Nazaret Sánchez-Sierra, Mercè Richarte-Franqués, Albert Català, Alba Crespo-Carrasco, José-Luis Dapena, Esther Cuatrecasas Capdevila, et al.

    Relapse remains the leading cause of treatment failure in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy. While prognostic factors for relapse have been identified, further refinement is needed. We conducted a single-center retrospective study of 69 patients treated with Tisagenlecleucel, to evaluate the prognostic impact of TP53 alterations (TP53Alt), including mutations and/or deletions. Among 49 patients with available samples, 17 (34.7%) had TP53Alt. These patients showed significantly lower remission rates (68.8% vs. 93.8%, p = 0.033) and worse event-free survival (EFS) and overall survival (OS), independent of genetic risk group. Median EFS was 3.8 months (95% CI: 1.2-NE) for TP53Alt versus 50.9 months (95% CI: 23.9-NE) for TP53 wild-type (TP53wt). Three-year EFS and OS were 33.1% (95% CI: 16.4%-66.6%) and 37.2% (95% CI: 19.4%-71.4%) for TP53Alt, compared to 56.2% and 81.2% for TP53wt (p = 0.0069 and p = 0.0010, respectively). These findings identify TP53 alterations as a strong adverse prognostic factor in patients with r/r B-ALL treated with CAR-T therapy. Screening for TP53Alt may guide risk-adapted strategies, including early consolidation with hematopoietic stem cell transplantation or alternative therapies.


  • Open Access

    Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups

    by Cristina Rivera-Pérez, Mireia Morgades, Anna Alonso-Saladrigues, Pau Montesinos, Thais Murciano, Cristina Gil, Rosa Adán, Jordi Esteve, Carolina Fuentes, María Luz Amigo, et al.

    Patients with relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) have very poor prognosis. CAR T-cell therapy is being explored in these patients with encouraging results. Specifically, CD1a-directed CAR T-cells are being explored in clinical trials to treat cortical T-ALL (CD1a+), but there are no data on outcome in this subgroup of patients before this therapy. This retrospective, observational study aimed to describe the characteristics and outcomes of patients with R/R CD1a + T-ALL. We included pediatric and adult patients diagnosed with R/R CD1a + T-ALL in 25 sites of Spain between March 2006 and May 2022. The primary outcome of the study was overall survival (OS). Forty-three patients, 28 adults and 15 children, with R/R CD1a + T-ALL were included. Median (range) age at inclusion was 24 years (5–57), and 82.5% were male. After a median (range) follow-up of 7.0 years (5.1–13.6), 6 (14.0%) patients were alive and in complete remission (CR) and 37 (86.0%) had died. Five-year OS was 16% (95% CI; 7–29%). Bone marrow relapse, an interval < 12 months between first CR and relapse, and lack of allogeneic hematopoietic stem cell transplantation during salvage treatment were associated with worse OS. Our results confirm that patients with R/R CD1a + T-ALL have a very poor prognosis, highlighting the need for new treatment alternatives in these patients.

  • Open Access

    Cross-border access to clinical trials: participation of pediatric patients and language inclusion

    by Begonya Nafria, Joana Claverol, Marta Cubells, Cristina Llanos, Laura Solé, Elisenda Sans, Sandra López, Jaume Catala-Mora, Susana Rives, Andrés Morales, et al.

    Cross-border access to clinical trials in Europe lacks specific regulation. Language diversity in Europe, with 24 official languages, is a key factor that must be considered when including international pediatric patients in multi-country studies. Providing translation enables patients to participate in clinical trials across borders. Specific consideration requires pediatric rare disease clinical trials for conditions with no approved treatment, where only a few countries participate, making cross-border access even more critical. We analyzed retrospective data (2011-2024) of the studies incorporating international patients at SJD Barcelona Children's Hospital. The main objective of this research was to assess the feasibility of cross-border access to pediatric clinical trials and identify lessons learnt that could help prevent the future exclusion of patients due to their limited proficiency in the official language of the country where the trial site is located. Twenty-one clinical studies have been analyzed. One hundred eighty-one patients from both European and non-European countries (N = 44) were screened, 37.02% of the patients were from Europe, versus 62.98% from non-European countries. In 52.38% of the studies, the translation services were provided by the site; in 14.28% by the sponsor. In 33.33% of the studies, no translation was necessary because the site staff could communicate with the families in Spanish or English. 57.14% of the studies included one or more PROMs or QoL scales, requiring, in some cases, the use of validated translations in the mother tongue of the patient. Participation in pediatric cross-border clinical trials is feasible. The decision to include international patients should prioritize potential medical benefits rather than using the patient's mother tongue or home country as eligibility criteria. Language barriers can be addressed by providing the necessary resources to ensure the scientific reliability of data collected, as well as to enhance the patient experience during participation in a trial abroad. The SJD Barcelona Children's Hospital Clinical Trials Unit operates under a one-stop-shop model, managing clinical studies with a special focus on rare diseases, centralizing all the needs of international patients (translations, accommodation, visas, etc.). The inclusion of international patients in pediatric clinical studies is feasible. Pediatric rare diseases require a small sample of patients, highly specialized sites, and flexibility to accommodate the necessary translations for patients. The final decision regarding the inclusion of international patients lies with the sponsor. Flexibility in including international patients directly impacts the study plan and execution, preventing time deviations.

  • Open Access

    Spanish Paediatric Haematology and Oncology Survival Results and Trends, 1999–2022

    by Pau Alfonso-Comos, Álvaro Briz-Redón, José Luis Dapena Díaz, Susana Rives, José María Fernández Navarro, Jaime Verdú-Amorós, Adela Cañete, RETI-SEHOP Survival Working Group

    Background: Childhood cancer is the leading cause of natural death among children in high-income countries, despite treatment improvements. The Spanish Registry of Childhood Tumours (RETI-SEHOP) systematically records all cases treated within the network of SEHOP units. Using RETI-SEHOP data, we evaluated survival trends to assess progress in patient care, both overall and by tumour. Methods: A total of 20,534 childhood cancer cases (0–14 years) were recorded across the period 1999–2021. The 1-, 3-, and 5-year overall survival (OS) were estimated using the Kaplan–Meier method, applying the cohort approach for 1999–2018 and the period approach for 2019–2022. OS by age and sex was analysed in the recent 2009–2018 incidence cohort. Age-adjusted OS time trends were examined using joinpoint Cox models for 1999–2022. Results: For all tumours combined, 5-year OS increased from 75.4% to 84.6% between 1999–2003 and 2019–2022. While positive trends were identified for all haematological malignancies examined, a more varied scenario was evident for solid tumours, as ependymomas improved fastest (1.51 points annually), and sarcomas, except for rhabdomyosarcoma, remained stagnant. Conclusions: Our results reflect a period characterised by a combination of new therapeutic developments, improved diagnostics, and more refined risk stratification, which has ultimately led to a reduction in disease-related mortality.